From The Stage

BioAgilytix Team Q&A: Meet Tatjana Ackermann, Quality Assurance Auditor

Dr. Arno Kromminga
Posted by Dr. Arno Kromminga / / BioAgilytix Insight, CRO Selection

We strive to foster an environment where our team members can continually grow within their role and within the company – not only upwards, but also into positions they come to find most suited to their unique skills and interests. In this Team Q&A session, we talk to Tatjana Ackermann, Quality Assurance Auditor, about her career path at BioAgilytix since starting in our European lab five years ago.

Platform Spotlight: ImmunoCAP to Support Diagnosis of Allergic Reactions Against Biologics

Dr. Arno Kromminga
Posted by Dr. Arno Kromminga / / Bioanalytical Platforms, Immunogenicity

The observation of drug-specific IgE antibodies which may cause anaphylaxis prompts the need to test for these antibodies - but because IgE are 2000-fold less prevalent than IgG antibodies, a very sensitive detection method is required. We discuss why the ImmunoCAP platform provides an ideal system to analyze IgE-mediated drug hypersensitivities.

Immunogenicity Assessment of Gene Therapy Compounds

Dr. Arno Kromminga
Posted by Dr. Arno Kromminga / / Gene Therapy, Industry Update

By Dr. Arno Kromminga and Dr. Lydia Michaut
Gene therapy has experienced an exciting resurgence in the post-genomic era, but unwanted immunogenicity is still a concern. Our latest blog gives insight into the current concepts for designing an immunogenicity assessment strategy fitting the specific needs of a given gene therapy compound.